Barchart.com
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
0.2001 -0.0115 (-5.43%) 14:58 ET [NASDAQ]
0.2012 x 200 0.2013 x 800
Realtime by (Cboe BZX)
0.2012 x 200 0.2013 x 800
Realtime 0.2040 -0.0076 (-) 09:29 ET
News & Headlines for Fri, Apr 11th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
X4 Pharmaceuticals: Q4 Earnings Snapshot AP - Tue Mar 25, 5:18AM CDT

X4 Pharmaceuticals: Q4 Earnings Snapshot

XFOR : 0.2001 (-5.43%)
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update GlobeNewswire - Tue Mar 25, 5:01AM CDT

XFOR : 0.2001 (-5.43%)
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025 GlobeNewswire - Tue Mar 11, 7:00AM CDT

XFOR : 0.2001 (-5.43%)
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries GlobeNewswire - Wed Feb 19, 6:35AM CST

XFOR : 0.2001 (-5.43%)
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia GlobeNewswire - Thu Feb 6, 6:35AM CST

XFOR : 0.2001 (-5.43%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Feb 3, 3:05PM CST

XFOR : 0.2001 (-5.43%)
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome GlobeNewswire - Fri Jan 24, 6:36AM CST

XFOR : 0.2001 (-5.43%)
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand GlobeNewswire - Mon Jan 13, 6:35AM CST

XFOR : 0.2001 (-5.43%)
X4 Pharmaceuticals to Present Pivotal Phase 3 Trial Data for Mavorixafor at ASH Annual Meeting 2024 Quiver Quantitative, Inc. - Wed Dec 4, 2024

X4 Pharmaceuticals announces presentations at the ASH Annual Meeting on mavorixafor for chronic neutropenia treatment.Quiver AI SummaryX4 Pharmaceuticals announced its participation in the 66th American...

XFOR : 0.2001 (-5.43%)
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition GlobeNewswire - Wed Dec 4, 2024

XFOR : 0.2001 (-5.43%)

Barchart Exclusives

Tesla Suspends Model X and S Orders in China. How Should You Play TSLA Stock Here? Barchart - 31 minutes ago
Tesla has stopped taking new orders for Model S and Model X in China amidst U.S.-China trade tensions. Could TSLA shares recover meaningfully in 2025? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot